Celgene Lands Big CAR-T Deal With Juno – At A Big Price
This article was originally published in The Pink Sheet Daily
Celgene is staking a leadership claim in immuno-oncology through a broad, 10-year collaboration with one of the leading CAR-T developers, Juno Therapeutics.
You may also be interested in...
Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.